LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
← catalyst calendarSponsored by Tenax Therapeutics, Inc. (industry) · TENX — their whole pipeline →. With Medpace, Inc., Northwestern University.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
230estimated
Sites
42
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-10 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Hypertension
Interventions
- Drug: TNX-103
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in Six-minute walk distance
measured 12 weeks
Permalink · TENX's whole pipeline · Catalyst calendar · Every registered study · What changed